May 6, 2020
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental New Drug Application (sNDA) for RECARBRIO in Hospital-Acquired or…